The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects
Abstract
Safety and pharmacokinetics (PK) of the antiparasitic drug ivermectin, administered in higher and/or more frequent doses than currently approved for human use, were evaluated in a double‐blind, placebo‐controlled, dose escalation study. Subjects (n = 68) were assigned to one of four panels (3:1, ivermectin/placebo): 30 or 60 mg (three times a week) or 90 or 120 mg (single dose). The 30 mg panel (range: 347–594 μg/kg) also received a single dose with food after a 1‐week washout. Safety assessments addressed both known ivermectin CNS effects and general toxicity. The primary safety endpoint was mydriasis, accurately quantitated by pupillometry. Ivermectin was generally well tolerated, with no indication of associated CNS toxicity for doses up to 10 times the highest FDA‐approved dose of 200 μg/kg. All dose regimens had a mydriatic effect similar to placebo. Adverse experiences were similar between ivermectin and placebo and did not increase with dose. Following single doses of 30 to 120 mg, AUC and C max were generally dose proportional, with t max ∼4 hours and t 1/2 ∼18 hours. The geometric mean AUC of 30 mg ivermectin was 2.6 times higher when administered with food. Geometric mean AUC ratios (day 7/day 1) were 1.24 and 1.40 for the 30 and 60 mg doses, respectively, indicating that the accumulation of ivermectin given every fourth day is minimal. This study demonstrated that ivermectin is generally well tolerated at these higher doses and more frequent regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1989) · Springer eBooks · doi:10.1007/978-1-4612-3626-9 · Cited by 841
Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus
Baraka, O. Z., Mahmoud, B. M., Marschke, C. K., Geary, T. G., Homeida, M. M. A., & Williams, J. F. (1996) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050131 · Cited by 146
Addiss, D. G., Beach, M. J., Streit, T. G., Lutwick, S., LeConte, F. H., Lafontant, J. G., Hightower, A. W., & Lammie, P. J. (1997) · The Lancet · doi:10.1016/s0140-6736(97)02231-9 · Cited by 116
A field study of the effects of ivermectin on ectoparasites of man
Dunne, C., Malone, C., & WHITWORTH, J. A. G. (1991) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(91)90255-w · Cited by 79
Tolerance and Efficacy of Single High-Dose Ivermectin for the Treatment of Loiasis
Martin‐Prével, Y., Cosnefroy, J., Tshipamba, P., Ngari, P., Chodakewitz, J., & Pinder, M. (1993) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1993.48.186 · Cited by 68
Richards, F. O., Eberhard, M. L., Bryan, R. T., McNeeley, D. F., Lammie, P. J., McNeeley, M. B., Bernard, Y., Hightower, A. W., & Spencer, H. C. (1991) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.1991.44.3 · Cited by 59
Ismail, M. M., Weil, G. J., Jayasinghe, K. S. A., Premaratne, U. N., Abeyewickreme, W., Rajaratnam, H. N., Sheriff, M. H. R., Perera, C., & Dissanaike, A. S. (1996) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(96)90437-x · Cited by 52
Awadzi, K., Hero, M., No, O., Dw, B., Pa, C., Ma, P., Ml, O., & Edwards, G. (1994) · PubMed · Cited by 46
Pharmacokinetics: A Modern View
Benet, L. Z. (1984) · Medical Entomology and Zoology · Cited by 45
Treatment failure of a single high dose of ivermectin for Mansonella perstans filariasis
den Enden, E. V., Gompel, A. V., der Stuyft, P. V., Vervoort, T., & den Ende, J. V. (1993) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(93)90438-v · Cited by 24
Cited by
A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection
Barrows, N. J., Campos, R. K., Powell, S. T., Prasanth, K. R., Schott-Lerner, G., Soto-Acosta, R., Galarza-Muñoz, G., McGrath, E. L., Urrabaz-Garza, R., Gao, J., et al. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.07.004 · Cited by 497
Moxidectin and the avermectins: Consanguinity but not identity
Prichard, R., Ménez, C., & Lespine, A. (2012) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2012.04.001 · Cited by 439
The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer
Yang, S. N. Y., Atkinson, S. C., Wang, C., Lee, A., Bogoyevitch, M. A., Borg, N. A., & Jans, D. A. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104760 · Cited by 322
Permethrin and ivermectin for scabies.
Currie, B. J., & McCarthy, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmct0910329 · Cited by 319
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
Metadata
- Authors
- Guzzo, C. A., Furtek, C. I., Porras, A. G., Chen, C., Tipping, R., Clineschmidt, C. M., Sciberras, D. G., Hsieh, J. Y., & Lasseter, K. C.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2002-10
- Volume
- 42
- Issue
- 10
- Pages
- 1122-1133
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2012188043
- Cited by
- 427
- References
- 12
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects. https://app.cochat.ai/papers/10.1177/009127002237994
- The paper
- Guzzo, C. A., Furtek, C. I., Porras, A. G., Chen, C., Tipping, R., Clineschmidt, C. M., Sciberras, D. G., Hsieh, J. Y., & Lasseter, K. C. (2002). Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects. The Journal of Clinical Pharmacology. https://doi.org/10.1177/009127002237994
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.